Systemic Psoriasis Therapeutics Industry 2020

1
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive
Growthby GBI Research

• Explore all reports for Dermatology therapeutic
  market
• _at_
• http//www.rnrmarketresearch.com/reports/life-scie
  nces/pharmaceuticals/therapeutics/dermatology-ther
  apeutics

2
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth

• The collection of Dermatology therapeutic
  market research reports has a new addition of
  Systemic Psoriasis Therapeutics in Major
  Developed Markets to 2020 Continued Uptake of
  Biologics and Novel Pipeline Drugs to Drive
  Growth on RnRMarketResearch.com. GBI Research
  has released its pharma report Systemic
  Psoriasis Therapeutics in Major Developed Markets
  to 2020 Continued Uptake of Biologics and Novel
  Pipeline Drugs to Drive Growth. The systemic
  psoriasis market is forecast to grow
  substantially over the forecast period from 5.0
  billion in 2013 to 10.4 billion in 2020, across
  the eight major markets. This growth will be
  driven by a rising treatment population and the
  continued uptake of biologics.
• Biologics will continue to drive market growth
  despite leading brands Enbrel (etanercept),
  Humira (adalimumab) and Remicade (infliximab)
  losing patent protection in most of the major
  markets over the forecast period.
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname148417 .

3
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth

• Although the market will suffer revenue losses as
  a result of sales erosion from biosimilar
  competitors, this will be offset by the emergence
  of novel therapies. Most notably, these include
  monoclonal antibodies secukinumab, ixekizumab and
  brodalumab, which are currently being developed
  by Alcon (Novartis subsidiary), Eli Lilly and
  Amgen, respectively.
• Scope
• An introduction to psoriasis, which includes
  symptoms, epidemiology, etiology,
  pathophysiology, diagnosis and treatment
• Analysis of the major systemic therapies in the
  current psoriasis marketed landscape
• Analysis of the pipeline for psoriasis, which
  includes a breakdown of pipeline molecules by
  phase of development, molecule type, molecular
  target and novelty.
• Complete Report is available _at_ http//www.rnrmarke
  tresearch.com/systemic-psoriasis-therapeutics-in-m
  ajor-developed-markets-to-2020-continued-uptake-of
  -biologics-and-novel-pipeline-drugs-to-drive-growt
  h-market-report.html

4
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth

•  Forecast projections for the systemic psoriasis
  market to 2020. Analysis is provided for the
  global market and each of the eight major
  markets. The forecast incorporates projected, low
  and high variance scenarios based on treatment
  usage patterns and annual therapy costs in each
  of the major markets.
• Analysis of strategic consolidations, including
  co-development and licensing deals, within the
  psoriasis indication
• Reasons to buy
• Understand the current systemic psoriasis
  marketed products landscape and recognize the
  dominant therapeutic agents and pharmaceutical
  players involved
• Identify trends and developments within the
  psoriasis pipeline and consider how the future
  competitive environment will be impacted
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname148417 .

5
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth

• Consider market opportunities and potential risks
  by examining the psoriasis clinical trial
  landscape in relation to industry averages
• Observe projections for treatment usage patterns,
  annual therapy costs and market growth in the
  eight major markets and understand reasons for
  variance in projected patterns of growth in the
  eight major markets
• Table of Contents
• 1 Table of Contents 41.1 List of Tables 61.2
  List of Figures 7
• 2 Introduction 82.1 Overview 82.2 Epidemiology
  92.3 Etiology, Co-morbidities and Risk Factors
  102.3.1 Genetics 102.3.2 Psoriatic Arthritis 10
• Complete Report is available _at_ http//www.rnrmarke
  tresearch.com/systemic-psoriasis-therapeutics-in-m
  ajor-developed-markets-to-2020-continued-uptake-of
  -biologics-and-novel-pipeline-drugs-to-drive-growt
  h-market-report.html

6
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth

• 2.3.3 Mental Health Disorders 112.3.4 Metabolic
  Syndrome, Smoking, Diet and Alcohol Consumption
  112.3.5 Infections 112.3.6 Köebner Phenomenon
  122.3.7 Other Immune-mediated Diseases 122.4
  Pathophysiology 122.5 Diagnosis 132.6 Treatment
  Options 132.6.1 Pharmacological Therapies
  142.6.2 Non-pharmacological Therapies 152.6.3
  Combination and Rotational Therapies 152.6.4
  Quality of Life Assessments 162.7 Summary 16
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname148417 .

7
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth

• 3 Marketed Products 173.1 Overview 173.2
  Methotrexate-based Products 173.3
  Sandimmune/Neoral (cyclosporine/modified
  cyclosporine) - Novartis 183.4 Soriatane
  (acitretin) - Steifel Laboratories 193.5
  Fumaderm (dimethyl fumarate and ethyl fumarate) -
  Biogen Idec 203.6 Humira (adalimumab) - Abbvie
  Inc. 213.7 Enbrel (etanercept) - Amgen Inc.
  223.8 Remicade (infliximab) - Janssen Biotech
  233.9 Stelara (ustekinumab) - Janssen Biotech
  243.10 Marketed Products Heat Map 25
• 4 Pipeline 284.1 Overview 28
• Complete Report is available _at_
  http//www.rnrmarketresearch.com/systemic-psoriasi
  s-therapeutics-in-major-developed-markets-to-2020-
  continued-uptake-of-biologics-and-novel-pipeline-d
  rugs-to-drive-growth-market-report.html

8
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.